Drugs / BMS-986419
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06846866 | Feb → Oct 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05963932 | Aug → Oct 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05932277 | Jun → Sep 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05847439 | May → Jul 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986419 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05932277 ↗ |